Highlights

  • Pacific Edge opens a NZ$6 million retail share offer for eligible existing shareholders.
  • Offer follows a NZ$25.4 million institutional Placement completed earlier in May 2026.
  • Funds aim to support Medicare re-coverage efforts and global commercial expansion.

Overview

Pacific Edge Limited (NZX:PEB) has launched a retail share offer to raise up to NZ$6 million from eligible existing shareholders, following a successful NZ$25.4 million institutional placement earlier in May 2026. Shares are offered at NZ$0.17, the same price as the placement. The Capital raising is intended to strengthen the company’s financial position and support its bladder cancer diagnostics Business, including efforts to regain Medicare coverage and expand adoption in the US and Asia-Pacific markets while continuing product development and innovation initiatives.

Why Is Pacific Edge Raising Additional Capital Through a Retail Offer?

Pacific Edge is raising additional capital to strengthen its Balance Sheet and support ongoing operational and strategic priorities. The funds will help the company advance its efforts to regain Medicare coverage, a key reimbursement pathway in the US healthcare system. It also aims to support continued clinical evidence generation, product innovation, and commercial expansion. By offering shares to existing shareholders at the same price as institutional investors, the company is maintaining fairness while broadening funding support for its growth strategy.

How Will the Capital Be Used to Support Pacific Edge’s Growth Strategy?

The capital raised will be directed toward strengthening Pacific Edge’s commercial and regulatory position in bladder cancer diagnostics. A key focus is restoring Medicare coverage in the United States, which is critical for wider adoption of its Cxbladder tests. Funds will also support research, development, and ongoing evidence generation to improve clinical acceptance. Additionally, the company plans to accelerate expansion across the US and Asia-Pacific regions while enhancing product innovation and maintaining momentum in its diagnostic pipeline.